Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 13/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 3/20 | 0.35 |
| ▸ | TNF | P01375 | 2/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | CLK3 | P49761 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL944241 | 0.80 | MAP3K5 (0.62) | MAP3K5TNF | |
| SCHEMBL23720763 | 0.76 | MAP3K5 (0.37) | MAP3K5TNFAKT1 | |
| SCHEMBL22739099 | 0.76 | MAP3K5 (0.43) | MAP3K5AKT1 | |
| SCHEMBL22739036 | 0.75 | MAP3K5 (0.39) | MAP3K5ABL1AKT1 | |
| SCHEMBL935947 | 0.72 | MAP3K5 (0.64) | MAP3K5TNF | |
| SCHEMBL22739076 | 0.72 | MAP3K5 (0.40) | MAP3K5TNFAKT1 | |
| SCHEMBL945883 | 0.72 | MAP3K5 (0.62) | MAP3K5GSK3B | |
| SCHEMBL23721029 | 0.71 | MAP3K5 (0.40) | MAP3K5AKT1 | |
| SCHEMBL944011 | 0.71 | MAP3K5 (0.55) | MAP3K5AKT1 | |
| SCHEMBL14553730 | 0.71 | MAP3K5 (0.62) | MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3363797-B1 | ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2020-12-02 | — | — | EP | disclosed |